Clinical trials
Tolerance clinical trials
Below are recruiting tolerance clinical trials, each written for real people, not researchers. We’re tracking 961 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06091254RecruitingPhase 3
Comparing odronextamab to standard chemo for untreated follicular lymphoma
This trial tests if a new drug called odronextamab is safe and works as well as a common antibody (rituximab) plus chemotherapy for people with a type of slow-growing lymphoma that hasn't been treated yet. It's for adults with grade 1-3a follicular lymphoma that is bulky stage II or stage III/IV.
Tucson, ArizonaAges 18 years+ - NCT06097065Recruiting
Finding diabetes and prediabetes markers in blood and urine
This study looks at leftover blood and urine samples to find new markers that could help detect prediabetes and diabetes earlier. It may lead to better testing and management.
Guangzhou, GuangdongAges Any age - NCT06102525RecruitingPhase 1/Phase 2
Testing RZ-001 with valganciclovir for glioblastoma
This trial tests a new treatment called RZ-001 combined with an antiviral drug (valganciclovir) for people with glioblastoma, a serious brain tumor. The goal is to see if the combination is safe and can help shrink or slow the tumor.
IncheonAges 18 years+ - NCT06116045RecruitingPhase 2
Study of BZ371A for women with sexual arousal disorder
This trial tests an investigational medication, BZ371A, to see if it can help women with Female Sexual Arousal Disorder (FSAD), a condition where they have trouble getting or keeping physical signs of arousal like lubrication and warmth. The study aims to find out if BZ371A is safe, effective, and well-tolerated.
Rio de Janeiro, Rio de JaneiroAges 21–60 - NCT06126744RecruitingPhase 1
Study of a virus therapy for recurrent brain cancer
This trial tests a virus-based treatment called MVR-C5252 for people whose high-grade glioma or glioblastoma has come back after standard therapy. The virus is injected directly into the tumor to try to kill cancer cells and boost the immune system. The goal is to see if it is safe and if it can shrink the tumor.
New York, New YorkAges 18 years+ - NCT06129240Recruiting
Study of a new inhaled treprostinil powder for PH-ILD
This study tests a new dry powder inhaled medicine called LIQ861 for people with pulmonary hypertension related to lung scarring (PH-ILD). If you are already taking an inhaled treprostinil treatment but need better control, this trial may help you switch to a potentially easier-to-use version.
Phoenix, ArizonaAges 18–80 - NCT06156046Recruiting
Understanding bee venom tolerance in beekeepers
This study looks at how beekeepers develop tolerance to bee venom over time, comparing people who are new to beekeeping, experienced beekeepers without allergies, and beekeepers who have had a recent allergic reaction. If you fall into one of these groups, you may be able to join and help researchers understand how the immune system adapts to bee stings.
Plymouth, DevonAges 18 years+ - NCT06161415RecruitingPhase 1
Laquinimod eye drops before vitrectomy: safety study
This trial tests a new eye drop called Laquinimod for people who are already scheduled for a vitrectomy. The drops are given before surgery to see if they are safe and how they spread in the eye.
Palo Alto, CaliforniaAges 18 years+ - NCT06163430RecruitingPhase 1/Phase 2
Testing a new pill for CML after other treatments
This study tests a new targeted pill called TERN-701 for people with chronic myeloid leukemia (CML) that has not responded well to or caused side effects from other targeted therapies. The goal is to see if it is safe and effective.
Birmingham, AlabamaAges 18 years+ - NCT06166056RecruitingPhase 1/Phase 2
Testing an inhaled medicine for bronchiectasis safety
This trial tests an inhaled medication for people with bronchiectasis, a lung condition causing chronic cough and mucus. It first checks safety in healthy volunteers, then studies how the drug works in people with bronchiectasis.
CambridgeAges 18–80 - NCT06167681RecruitingPhase 1/Phase 2
Cell Therapy NouvNeu001 for Parkinson's Disease
This trial tests a new cell therapy called NouvNeu001 for Parkinson's disease. It involves a one-time brain surgery to deliver the treatment, and researchers will check if it's safe and helps with symptoms.
Beijing, Beijing MunicipalityAges 50–75 - NCT06184373Recruiting
Early glucose monitoring after gestational diabetes pilot
This study tests a continuous glucose monitor (a small patch that tracks your blood sugar) for a few weeks after you give birth. It aims to see if this tool can help women who recently had gestational diabetes better understand their blood sugar levels after delivery.
Columbus, OhioAges 18–50 - NCT06186414RecruitingPhase 1
SIM0237 with or without BCG for bladder cancer
This trial tests a new drug, SIM0237, alone or with BCG, for people with a type of bladder cancer called non-muscle invasive bladder cancer (NMIBC) that did not respond to BCG treatment. The goal is to see if it is safe and works against the cancer.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06191432Recruiting
Testing an ancient grain for people sensitive to wheat
This study tests how well people with non-celiac wheat sensitivity tolerate a special ancient grain. Researchers want to see if this grain causes fewer or less bothersome symptoms than modern wheat.
Palermo, SicilyAges 18–65 - NCT06204237RecruitingEarly Phase 1
PET imaging safety study for leg artery disease patients and healthy volunteers
This study tests whether a new radioactive tracer called APAC is safe and can be seen in PET/CT scans. It is for people with blocked leg arteries (PAOD/CLI) and for healthy volunteers. The goal is to see where the tracer goes in the body and how the body tolerates it.
GroningenAges 40–85 - NCT06207552RecruitingEarly Phase 1
Gene therapy study for children with Fabry disease
This study tests a new gene therapy for children aged 7 to 17 with Fabry disease. The treatment aims to fix the faulty gene that causes the condition, which may help reduce symptoms and prevent organ damage.
ShanghaiAges 7–18 - NCT06212427Recruiting
Preterm infant formula with human milk sugars
This study tests a special supplement added to preterm infant feeding. The supplement contains beneficial sugars found in breast milk, which may help babies digest better and grow. It is for premature babies who have started small feedings but are not yet fully feeding.
LinzAges birth–2 weeks - NCT06216041RecruitingPhase 1
Safety study of IMM-H014 in healthy adults
This trial tests a new drug called IMM-H014 in healthy volunteers to see if it is safe and how the body processes it. It also checks if food changes how the drug works. You may join if you are generally healthy and meet the age and weight requirements.
Changchun, JilinAges 18–45 - NCT06217757RecruitingPhase 1/Phase 2
LDRT, immunotherapy, chemo, and olaparib for SLFN-11 positive SCLC
This trial tests a combination of low-dose radiation, an immunotherapy drug (sugemalimab), chemotherapy, and a targeted drug (olaparib) as a first treatment for people with extensive-stage small cell lung cancer that has a specific marker called SLFN-11. The goal is to see if this combination is safe and works better than standard treatment.
Chengdu, SichuanAges 18–75 - NCT06218784RecruitingPhase 1
Testing a new drug for safety in healthy people and those with nerve pain after shingles
This study tests an experimental drug, iN1011-N17, to see how safe it is and how the body processes it. It involves healthy volunteers and people with postherpetic neuralgia (nerve pain after shingles). This may help find better treatments for this type of chronic pain.
Adelaide, South AustraliaAges 18–75 - NCT06225804RecruitingPhase 1
Study of ABSK112 for advanced non-small cell lung cancer
This trial tests a new drug called ABSK112 for people with advanced non-small cell lung cancer, especially those whose cancer has a specific change in the EGFR gene (exon 20 insertion). The main goals are to see if it's safe and how the body handles it.
Beverly Hills, CaliforniaAges 18 years+ - NCT06235437RecruitingPhase 1
Testing a new drug (ASD141) for advanced solid tumors
This early-phase trial tests a new drug called ASD141 for people with advanced solid tumors that no longer respond to standard treatments. The goal is to see if it is safe and how well it works against the cancer.
TainanAges 18 years+ - NCT06236880RecruitingPhase 2
Testing GM-2505 for Moderate to Severe Depression
This trial tests a new oral medication, GM-2505, for people with moderate to severe major depressive disorder (MDD). The goal is to see if it is safe and well-tolerated, either as a stand-alone treatment or alongside a stable SSRI/SNRI antidepressant.
ManchesterAges 18–65 - NCT06240195Recruiting
Study of sacituzumab govitecan for advanced triple-negative breast cancer
This study is testing a drug called sacituzumab govitecan (SG) for people with advanced triple-negative breast cancer who have already had other treatments. The goal is to see how well the drug works and what side effects it causes, using your tumor samples to look for clues (biomarkers).
Rome, RomeAges 18 years+
Hear when a new Tolerance trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for tolerance?
- Yes. Clin2 currently lists 961 recruiting tolerance studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a tolerance trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a tolerance trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.